JCOGの基本情報 > 研究実績 > 乳がんグループ

JCOGの基本情報乳がんグループ

更新日：2017年10月27日

  1. 論文
    1. 委員会承認の治療研究
      JCOG8808
      N Yamamoto, T Watanabe, N Katsumata, et al.: Construction and Validation of a Practical Prognostic Index for Patients with Metastatic Breast Cancer. J Clin Oncol. 16: 2461-2408, 1998.
      H Okamura, N Yamamoto, T Watanabe, et al.: Patients’ understanding of their own disease and survival potential in patients with metastatic breast cancer. Breast Cancer Res Treat. 61: 145-150, 2000.
      JCOG9107
      S Takashima, T Saeki, I Adachi, et al.: A Phase II Study of High-dose Epirubicin (EPI) plus Cyclophosphamide (CPA) with G-CSF for Breast Cancer Patients with Visceral Metastases or Hormone-independent Tumors: A Trial of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 27(5): 325-330, 1997.
      JCOG9113
      T Ikeda, I Adachi, S Takashima, et al.: A phase I/II Study of Continuous Intra-arterial Chemotherapy Using an Implantable Reservoir for the Treatment of Liver Metastases from Breast Cancer: A Japan Clinical Oncology Group (JCOG) Study 9113. Jpn J Clin Oncol. 29(1): 23-27, 1999.
      JCOG9208
      Y Tokuda, T Tajima, M Narabayashi, et al.: Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci. 99: 145-151, 2008.
      JCOG9401
      T Shien, H Iwata, K Aogiet al.: Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401). Int J Clin Oncol. Jan 2014. [Epub ahead of print].
      JCOG9404
      T Shien, H Iwata, T Fukutomi, et al.: Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404. Cancer Chemother Pharmacol. 74(3): 603-609, 2014.
      JCOG9802
      N Katsumata, T Watanabe, H Minami, et al.: Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan ClinicalOncology Group trial (JCOG9802). Ann Oncol. 20(7): 1210-1215, 2009.
      JCOG0306
      H Mukai, T Watanabe, M Mitsumori, et al.: Final results of a safety and efficacy trial of preoperative sequential chemo-radiation therapy for the nonsurgical treatment in early breast cancer: Japan Clinical Oncology Group Study JCOG0306. Oncology. 85(6): 336-341, 2013.
      JCOG1017
      T Shien, K Nakamura, T Shibata, et al.: A Randomized Controlled Trial Comparing Primary Tumour Resection Plus Systemic Therapy With Systemic Therapy Alone in Metastatic Breast Cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol. 42(10): 970-973, 2012.
      T Shien, H Doihara: Resection of the primary tumor in stage IV breast cancer. World J Clin Oncol. 5(2): 82-85, 2014.
      T Shien, H Iwata .: Significance of primary lesion resection in Stage IV breast cancer. Jpn J Clin Oncol. 1;47(5):381-384, 2017.
      JCOG1204
      T Hojo, N Masuda, T Mizutani, et al.: Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204. Jpn J Clin Oncol. 45(10): 983-986, 2015.
      JCOG1505
      C Kanbayashi, H Iwata.: Current approach and future perspective for ductal carcinoma in situ of the breast. Jpn J Clin Oncol. 9; 47:1-7, 2017.
    2. グループ代表者管理の治療研究
      A Kohno, K Takeyama, M Narabayashi, et al.: Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplant. 15: 49-54, 1995.
      H Iwata: The Transition of Breast Cancer Treatment and Japan Clinical Oncology Group Research Over Two Decades. Jpn J Clin Oncol. 42(1): 14-20, 2012.
      N Niikura, N Hayashi, N Masuda, et al.: Treatment Outcomes and Prognostic Factors for Patients with Brain Metastasesfrom Breast Cancer of Each Subtype: A Multicenter Retrospective Analysis. Breast Cancer Res Treat. 147(1): 103-112, 2014.
      N Niikura, S Saji, Y Tokuda, et al.: Brain metastases in breast cancer. Jpn J Clin Oncol. 44(12);1133-1140, 2014.
      N Hayashi, N Niikura, N Masuda, et al.: Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. Breast Cancer Res Treat. 149(1): 277-284, 2015
    3. 附随研究等
      M Narabayashi, K Takeyama, T Fukutomi, et al.: A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Jpn J Clin Oncol. 29: 285-290, 1999.
    4. 総説・解説
      飛内賢正: 4. Dose Intensive Chemotherapyによる治癒率向上の試み. ③ rhG-CSFと自家骨髄移植を併用した大量化学療法の試み : 再発乳癌及びHigh Risk胚細胞腫瘍患者の治癒を目指して. 垣添忠生、下山正徳 監修、薬物療法を主体とする固形がんの集学的治療の臨床試験研究. 協和企画通信. 220-233, 1991.
      飛内賢正: Debate Corner－固形がんに対するPBSCT: 意義があるとする立場から. 血液・免疫・腫瘍. 4: 122-126, 1999.
      高嶋成光、青儀健二郎、佐伯俊昭: 日本における乳癌薬物療法の臨床試験. 癌の臨床. 46: 1163-1170, 2000
      枝園忠彦: Ongoing clinical study JCOG1017試験"PRIM-BC"(薬物療法非抵抗性stage IV乳癌に対する原発巣切除の意義[原発巣切除なしversusあり]に関するランダム化比較試験). Cancer Board 乳癌(1883-1699). 5(1): 75-76, 2012.
      岩田広治.: JCOGでの新たな取り組み. 医学のあゆみ. 2017.
  2. 主な学会発表
    1. 委員会承認の治療研究
      JCOG9006
      徳田 裕、田島知郎、奈良林 至、他: 進行再発癌に対する自家造血幹細胞移植を併用した大量化学療法の多施設共同第II相試験 （JCOG study 9006；ABMT-BCプロトコール）：治療成績の中間解析. 第33回日本癌治療学会総会. 1995年9月
      奈良林 至、竹山邦彦、安達 勇、他: 進行再発乳がんに対する自家造血幹細胞移植を併用した大量化学療法の多施設共同第II相試験 （JCOG study 9006；ABMT-BCプロトコール）：その毒性, 安全性について. 第33回日本癌治療学会総会. 1995年9月.
      JCOG9208
      Y Tokuda, T Tajima, M Narabayashi, et al.: Randomized phase III study of high-dose chemotherapy with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan Clinical Oncology Group (JCOG9208). 37th Annual Meeting of the American Society of Clinical Oncology. May 2001.
      JCOG9113
      池田 正、安達 勇、荻田征美、他: 乳癌肝転移症例に対する動注療法のphase I study. 第33回日本癌治療学会総会. 1995年9月.
      JCOG9114
      N Katsumata, T Watanabe, M Sano, et al.: Evaluation of addition of Medroxyprogesterone Acetate (MPA) at two doses to the chemoendocrine therapy with Doxorubicin (A), Cyclophosphamide (C) and Tamoxifen (TAM) in metastatic breast cancer. 36th Annual Meeting of the American Society Clinical Oncology. May 2000.
      JCOG 9802
      N Katsumata, H Minami, K Aogi, et al.: Phase III trial of doxorubicin (A)/cyclophosphamide (C) (AC), docetaxel (D),and alternating AC and D (AC-D) as frontline chemotherapy for metastatic breast cancer (MBC): Japan Clinical Oncology Group trial (JCOG9802), 41st Annual Meeting of the American Society of Clinical Oncology. May 2005.
      JCOG 0306
      H Mukai, T Watanabe, M Mitsumori, et al.: Safety and efficacy trial of preoperative sequential chemo-radiation therapy for the nonsurgical treatment (NST)in early breast cancer (EBC): Japan Clinical Oncology Group trial (JCOG 0306) , 44th Annual Meeting of the American Society of Clinical Oncology. May 2008.
      H Mukai, T Watanabe, M Mitsuimori, et al.: Final analysis of safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment (NST) in early breast cancer (EBC): Japan Clinical Oncology Group Trial (JCOG0306). 46th Annual Meeting of the American Society of Clinical Oncology. Jun 2010.
      JCOG1017
      枝園忠彦、木下貴之、平成人、他: Stage IV乳癌に対する外科治療の位置付け 薬物療法非抵抗性Stage IV乳癌に対する原発巣切除の意義(原発巣切除なしversusあり)に関するランダム化比較試験:JCOG1017. 第112回 日本外科学会学術総会. 2012年4月
      T Shien, H Kinoshita, T Doihara, et al.: The efficacy of primary tumor resection and prognosis of stage IV breast Cancer. International surgical week 2013. Aug 2013.
      T Shien.: Management and clinical trial for stage IV breast cancer in Japan. Seoul Breast Cancer Symposium. Sep 2013.
      T Shien, H Iwata, K Nakamura, et al.: A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (JCOG1017 study; PRIM-BC). 37th San Antonio Breast Cancer Symposium. Dec 2014.
      T Shien, H Iwata, Y Abe, et al.: What is the effective primary resection for Stage IV breast cancer? : The evaluation of aim and timing of surgery. Asian Breast Cancer Conference 2014. Oct 2014.
      T Shien, H Iwata, Y Abe, et al.: Evaluation of Treatment Strategy for Stage IV Breast Cancer Patients. International Surgical Week 2015 World congress of surgery. Aug 2015.
      T Shien, T Mizutani, K Tanaka, et al.: A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer [PRIM-BC]: Japan Clinical Oncology Group Study JCOG1017 (Trial in Progress). 53th Annual Meeting of the American Society of Clinical Oncology. Jun 2017.
      JCOG1204
      T Hojo, K Tamura,N Masuda, et al.: Survival impact of early detection of recurrence after surgery in early breast cancer patients. 35th San Antonio Breast Cancer Symposium. Dec 2012.
    2. グループ代表者管理の治療研究
      R Oogia, N Niikura, N Kumaki, et al.: Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. 53th Annual Meeting of the American Society of Clinical Oncology. Jun 2017.
    3. 附随研究等
      竹山邦彦、飛内賢正、奈良林 至、他: 乳がんに対するadjuvant chemotherapy（CAF療法）後の末梢血幹細胞動態：rhG-CSF （lenograstim）のdose finding studyの中間解析. 第57回日本血液学会総会. 1995年6月.
      Y Tokuda, K Tobinai, K Takeyama, et al.: Dose finding study of figrastim to mobilize PBSC with or without chemotherapy in stage IV breast cancer patients. 32nd Annual Meeting of the American Society of Clinical Oncology. May 1996.
      竹山邦彦、飛内賢正、徳田 裕、他： 進行再発乳がん患者におけるG-CSF mobilizingによる末梢血幹細胞動態：G-CSF単独及びchemotherapyとの併用におけるdose finding study. 第58回日本血液学会総会. 1996年4月.
      奈良林 至、竹山邦彦、徳田 裕、他: 乳がん患者における末梢血幹細胞採取のためのG-CSFの至適用量の検討. 第35回日本癌治療学会. 1997年10月.
      奈良林 至、竹山邦彦、五十嵐忠彦、他: 乳がん患者に対する術後化学療法施行時の末梢血幹細胞採取におけるレノグラスチムの至適投与量の検討. 第20回日本造血細胞移植学会. 1997年12月.
      張 高明、奈良林 至、田島知郎、他: 乳がん術後化学療法施行時の末梢血幹細胞（PBSC）動員におけるレノグラスチムの推奨用量の最終検討結果. 第22回日本造血細胞移植学会. 1999年12月.
    4. 総説・解説
      徳田 裕、田島知郎、奈良林 至、他: 乳癌に対する自家造血幹細胞移（AHSCT）を併用した大量化学療法の現況と問題点. 第35回日本癌治療学会. 1997年10月.
      奈良林 至、飛内賢正: 自家末梢血幹細胞移植：固形腫瘍. 第5回日本輸血学会秋季シンポジウム. 1997年11月.
      高嶋成光: Japan Clinical Oncology Group(JCOG) で行った乳がん薬物療法の臨床試験. 第102回日本外科学会総会. 2002年4月.
      K Aogi: JCOG Breast Cancer Study: Clinical Trials in Breast Cancer sponsored by MHLW International Session10　Breast Cancer. 第9回日本臨床腫瘍学会. 2011年7月.
トップへ戻る